Turn Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

TTRX$9.92+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

Total
Common Stock · Additional · Subscription · Accumulated · Stockholders’
Shares · Amount · Paid-in Capital · Receivable · Deficit · Equity
As at December 31, 2025	29,445,183	$2,943	$28,143,873		$(1,070,000)	$(22,390,093)	$4,686,723
Issuance of common stock under Avenue Capital Agreement	342,857	34	1,050,933		-	-	1,050,967
Cash receipt from stock subscription receivable	-	-	-		1,070,000	-	1,070,000
Stock-based compensation expense	-	-	700,063		-	-	700,063
Net loss	-	-	-		-	(6,820,865)	(6,820,865)
As at June 30, 2026	29,788,040	$2,977	$29,894,869	$	-	$(29,210,958)	$686,888

Total
Common Stock · Additional · Subscription · Accumulated · Stockholders’
Shares* · Amount* · Paid-in Capital · Receivable · Deficit · Equity (Deficit)
As at December 31, 2024	26,845,690	$2,684	$19,015,897	$	-	$(19,196,013)	$(177,432)
Issuance of common stock under Regulation Crowdfunding, net of issuance costs	215,972	22	777,781				777,803
Issuance of common stock under Regulation A+, net of issuance costs	83,610	8	280,484		(247,234)		33,258
Issuance of common stock under Regulation D, net of issuance costs	775,468	78	2,735,824		(400,082)		2,335,820
Issuance of common stock in exchange for advisory services	54,466	5	249,995				250,000
Issuance of common stock upon exercise of warrants	47,620	5	233				238
Stock-based compensation expense	-	-	123,781				123,781
Net loss	-	-	-		-	(1,568,972)	(1,568,972)
As at June 30, 2025	28,022,826	$2,802	$23,183,995		$(647,316)	$(20,764,985)	$1,774,496

*	Retroactively adjusted for 2-for-1 forward stock split.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.